Trial
NCT06504966
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Xentria, Inc.
Collaborators
—
Condition
Osteoporosis
Intervention
MAB-22
Why stopped
Business decision not to proceed with the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-11